Compare Stocks: BCRX, SYRE, TGTX, and CYTK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.02 -0.4%	$9.05	$6.23 ▼ $11.22	$2.06B	0.55	5.34 million shs	4.50 million shs
CYTK Cytokinetics	$63.92 +0.8%	$70.48	$54.30 ▼ $88.31	$7.89B	0.41	2.30 million shs	1.67 million shs
SYRE Spyre Therapeutics	$80.10 +1.9%	$92.49	$21.15 ▼ $110.18	$8.01B	3.1	1.64 million shs	1.15 million shs
TGTX TG Therapeutics	$56.00 +3.0%	$54.18	$26.76 ▼ $59.30	$8.32B	1.8	1.80 million shs	1.81 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-0.37%	-3.26%	-1.72%	-13.67%	+17.77%
CYTK Cytokinetics	+0.77%	+3.08%	-7.78%	-20.28%	+1.78%
SYRE Spyre Therapeutics	+1.87%	+0.25%	-11.93%	-20.08%	+260.97%
TGTX TG Therapeutics	+3.00%	+4.99%	+5.58%	+2.06%	+59.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.02 -0.4%	$9.05	$6.23 ▼ $11.22	$2.06B	0.55	5.34 million shs	4.50 million shs
CYTK Cytokinetics	$63.92 +0.8%	$70.48	$54.30 ▼ $88.31	$7.89B	0.41	2.30 million shs	1.67 million shs
SYRE Spyre Therapeutics	$80.10 +1.9%	$92.49	$21.15 ▼ $110.18	$8.01B	3.1	1.64 million shs	1.15 million shs
TGTX TG Therapeutics	$56.00 +3.0%	$54.18	$26.76 ▼ $59.30	$8.32B	1.8	1.80 million shs	1.81 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-0.37%	-3.26%	-1.72%	-13.67%	+17.77%
CYTK Cytokinetics	+0.77%	+3.08%	-7.78%	-20.28%	+1.78%
SYRE Spyre Therapeutics	+1.87%	+0.25%	-11.93%	-20.08%	+260.97%
TGTX TG Therapeutics	+3.00%	+4.99%	+5.58%	+2.06%	+59.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.45	Hold	$19.44	142.45% Upside
CYTK Cytokinetics	2.86	Moderate Buy	$105.44	64.96% Upside
SYRE Spyre Therapeutics	2.94	Moderate Buy	$110.40	37.83% Upside
TGTX TG Therapeutics	2.56	Moderate Buy	$63.00	12.50% Upside

Current Analyst Ratings Breakdown

Latest BCRX, SYRE, TGTX, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	CYTK Cytokinetics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/14/2026	CYTK Cytokinetics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$104.00
10/11/2026	SYRE Spyre Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$120.00
10/11/2026	SYRE Spyre Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/8/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/8/2026	CYTK Cytokinetics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$112.00 ➝ $113.00
10/6/2026	TGTX TG Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/1/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$121.00
10/1/2026	SYRE Spyre Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$110.00
9/30/2026	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$12.00 ➝ $13.00
9/22/2026	BCRX BioCryst Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C) ➝ Sell (D-)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$874.84M	2.34	$1.23 per share	6.50	($0.57) per share	-14.07
CYTK Cytokinetics	$88.04M	90.34	N/A	N/A	($5.39) per share	-11.86
SYRE Spyre Therapeutics	$890K	9,171.90	N/A	N/A	$7.21 per share	11.11
TGTX TG Therapeutics	$616.29M	13.91	$2.89 per share	19.40	$4.08 per share	13.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	$263.86M	-$1.50	N/A	11.62	N/A	-40.90%	-86.89%	66.37%	11/2/2026 (Estimated)
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	20.44	21.13	2.30	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest BCRX, SYRE, TGTX, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	CYTK Cytokinetics	-$1.45	N/A	N/A	N/A	$40.61 million	N/A
11/3/2026	Q3 2026	SYRE Spyre Therapeutics	-$0.7767	N/A	N/A	N/A	N/A	N/A
11/2/2026	Q3 2026	BCRX BioCryst Pharmaceuticals	$0.0903	N/A	N/A	N/A	$165.67 million	N/A
11/2/2026	Q3 2026	TGTX TG Therapeutics	$0.3663	N/A	N/A	N/A	$245.47 million	N/A
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/5/2026	Q2 2026	BCRX BioCryst Pharmaceuticals	$0.1542	$0.30	+$0.1458	$0.30	$183.28 million	$218.25 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.32	2.29
CYTK Cytokinetics	N/A	6.66	6.66
SYRE Spyre Therapeutics	N/A	18.53	18.53
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
CYTK Cytokinetics	N/A
SYRE Spyre Therapeutics	80.39%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	3.80%
CYTK Cytokinetics	2.60%
SYRE Spyre Therapeutics	15.69%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	435	255.54 million	245.83 million	Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
SYRE Spyre Therapeutics	112	101.91 million	85.92 million	Optionable
TGTX TG Therapeutics	399	153.07 million	139.49 million	Optionable

BCRX, SYRE, TGTX, and CYTK Headlines

Recent News About These Companies

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

October 13 at 11:51 AM | zacks.com

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

October 12, 2026 | businesswire.com

Tg Therapeutics, Inc. Announces Schedule of Data Presentations At Mstoronto2026

October 9, 2026 | marketscreener.comM

TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow

October 9, 2026 | finance.yahoo.com

TG Therapeutics (TGTX) Just Sparked A Bigger Question

October 8, 2026 | finance.yahoo.com

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

October 8, 2026 | businesswire.com

TG Therapeutics (NASDAQ:TGTX) Stock Rating Raised to Hold at Zacks Research

October 8, 2026 | americanbankingnews.com

TG Therapeutics (NASDAQ:TGTX) Raised to Hold at Zacks Research

October 8, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Stock Breaks Above 200-Day Moving Average - Here's What Happened

October 6, 2026 | americanbankingnews.com

TG Therapeutics (NASDAQ:TGTX) Shares Break Above 200 Day Moving Average - Should You Sell?

October 6, 2026 | marketbeat.com

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

September 28, 2026 | prnewswire.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts

September 27, 2026 | marketbeat.com

TG Therapeutics Inc (TGTX)

September 24, 2026 | ru.investing.com

Dow Jones futures fall after Nasdaq hits new high; SanDisk, Micron trigger buy signals

September 23, 2026 | msn.com

Dow Jones futures: Nasdaq hits new high; SanDisk, Micron trigger buy signals

September 22, 2026 | msn.com

Bank of America Corp DE Acquires Shares of 1,309,788 TG Therapeutics, Inc. $TGTX

September 20, 2026 | marketbeat.com

Tidal Investments LLC Buys New Holdings in TG Therapeutics, Inc. $TGTX

September 19, 2026 | marketbeat.com

TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound

September 18, 2026 | finance.yahoo.com

TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

September 18, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Trading 8.3% Higher - Here's Why

September 16, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Director Sells 5,000 Shares

September 15, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX, SYRE, TGTX, and CYTK Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.02 -0.03 (-0.37%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$8.14 +0.12 (+1.53%)

As of 04:41 AM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Cytokinetics NASDAQ:CYTK

$63.92 +0.49 (+0.77%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$63.92 0.00 (0.00%)

As of 10/15/2026 07:30 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Spyre Therapeutics NASDAQ:SYRE

$80.10 +1.47 (+1.87%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$80.12 +0.03 (+0.03%)

As of 10/15/2026 07:30 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$56.00 +1.63 (+3.00%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$56.00 0.00 (0.00%)

As of 04:03 AM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCRX, SYRE, TGTX, and CYTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCRX, SYRE, TGTX, and CYTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCRX, SYRE, TGTX, and CYTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX, SYRE, TGTX, and CYTK Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

Cytokinetics NASDAQ:CYTK

Spyre Therapeutics NASDAQ:SYRE

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCRX, SYRE, TGTX, and CYTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCRX, SYRE, TGTX, and CYTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCRX, SYRE, TGTX, and CYTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX, SYRE, TGTX, and CYTK Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

Cytokinetics NASDAQ:CYTK

Spyre Therapeutics NASDAQ:SYRE

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools